ALT

Altimmune Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.

Did you know?

Currently operating at a negative 244702.8% profit margin.

Current Price

$2.82

+8.46%

GoodMoat Value

$0.00

99.9% overvalued

Profile

Valuation (TTM)

Market Cap$294.00M

P/E-3.34

EV—

P/B1.31

Shares Out104.25M

P/Sales8166.58

Revenue$36000.00

EV/EBITDA—

Altimmune Inc (ALT) Financial Statements

ALT Financial Data

EBITDA$-87.03M

Revenue (TTM)$36000.00

Gross Profit (TTM)$36000.00

Gross Margin—

Operating Margin-230460.98%

ROE-39.17%

ROA-31.47%

Debt/Equity0.15

Current Ratio18.55

FCF$-67.55M

FCF Yield-22.98%

Piotroski F-Score—

Rev/Share (TTM)$0.00

50-Day MA$3.49

200-Day MA$4.03

Shares Outstanding0.10B

ALT Computed Insights

FCF$-67.55M

FCF Growth Rate—

EPS Growth (CAGR)—

WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

ALT Financial Statements & Data

Altimmune Inc (ALT) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Altimmune Inc's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $36000.00. Gross profit (TTM) is $36000.00. EBITDA is $-87.03M. Earnings per share (EPS) is $-1.00. The P/E ratio is -3.34. Market capitalization is $294.00M.

Free cash flow (FCF) is $-67.55M. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Altimmune Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.